Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Baricitinib in the Post-intracerebral Hemorrhage Pulmonary Injury

NCT06548802 is registered in ClinicalTrials.gov with Tianjin Medical University General Hospital as lead sponsor.

NCT NCT06548802
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06548802 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Baricitinib in the Post-intracerebral Hemorrhage Pulmonary Injury
Lead sponsor
Tianjin Medical University General Hospital
Phase
Phase 1/2
Overall status
Recruiting
Start date
February 29, 2024
Completion date
June 30, 2026
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary injury after intracerebral hemorrhage